BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform…
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…
– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m.…
Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study…
Hanna Longstaff Founder of Mind Food Body Ltd KENT, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Mind Food Body…
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the…
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy…
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared…
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared…
Phase 2 study results to be presented at The Liver Meeting® 2024 of AASLD BJT-778 900 mg dosed every four weeks…